About
Pediatric Leukemias and Lymphomas
Course Introduction
About this course
Paediatric leukemias and lymphomas represent some of the most clinically complex haematological malignancies — where evolving combination regimens, emerging targeted therapies, and case-by-case decision-making converge in the management of vulnerable young patients.
Paediatric leukemias and lymphomas represent some of the most clinically complex haematological malignancies — where evolving combination regimens, emerging targeted therapies, and case-by-case decision-making converge in the management of vulnerable young patients.
This programme covers the contemporary landscape of paediatric leukemias and lymphomas — covering evolving treatment regimens, the role of BTK and BCL-2 inhibitors, IV and oral therapy combinations, and the clinical and economic considerations that shape management decisions.
🎯 Built for clinical readiness. Concise, structured, and skill-focused — designed to translate directly into safer, more confident clinical practice.
What this programme covers
Scope of the Course
What this course covers
This programme spans paediatric leukemias and lymphomas — including chronic and acute leukemia treatment regimens, expanding combination approaches, the role of targeted therapies including BTK and BCL-2 inhibitors, finite treatment intervals, IV and oral regimen choices, adverse-effect management, formulary and resource utilisation considerations, and the case-based approach to clinical decision-making in CLL and related conditions.
🧠
Why this scope matters
This programme covers the contemporary landscape of paediatric leukemias and lymphomas — covering evolving treatment regimens, the role of BTK and BCL-2 inhibitors, IV and oral therapy combinations, and the clinical and economic considerations that shape management decisions.
Learning objectives
Course Objectives & Outcomes
What you will achieve
By the end of this course, learners will have built core clinical competencies directly applicable to everyday practice — translating into safer, more confident, more effective patient care.
Each outcome below targets a specific dimension of paediatric haemato-oncology practice — building integrated competence across treatment selection, monitoring, and complication management.
By the end of this course, learners will be able to:
01
Recognise the contemporary treatment landscape for paediatric leukemias and lymphomas
02
Apply chemo-immunotherapy combination regimens with awareness of efficacy and adverse-effect considerations
03
Evaluate the role of BTK and BCL-2 inhibitor therapies in paediatric haemato-oncology
04
Differentiate between IV and oral therapy combinations for individual patient scenarios
05
Apply patient-specific decision frameworks for regimen selection and dose adjustment
06
Coordinate formulary management and resource utilisation strategies in paediatric haemato-oncology
07
Apply evidence-based approaches to managing the burgeoning treatment arsenal for CLL patients
Smarter regimens. Better outcomes. Stronger paediatric care.
Build clinical confidence one skill at a time.
Who can enroll
Who Can Enroll
Built for these learners
This course is designed for healthcare learners and professionals seeking practical, skill-focused clinical training.
This programme is built for paediatric oncologists, haematologists, oncology pharmacists, oncology nurses, healthcare administrators and clinical professionals involved in paediatric haemato-oncology care.
Designed for these learners
🧑⚕️
01
Paediatric oncologists and haematologists
👨⚕️
02
Oncology pharmacists
🦹
04
Healthcare administrators
💊
05
Clinical professionals in paediatric haemato-oncology
Sharper Skills. Stronger Practice.
Take the next step in your clinical journey with structured, skill-focused training.
Programme Certification
Your certificate
Upon successful completion of this programme, you will receive a digital certificate recognising your achievement and the competencies you have acquired throughout the course.
Certificates for TerraLeap programmes are issued and signed by authorised TerraLeap representatives. For programmes delivered in collaboration with universities, institutions, or industry organisations, certificates are jointly issued and co-signed by authorised representatives of both TerraLeap and the respective partner.
Each certificate carries a unique Certificate ID and QR code to enable instant authenticity verification — making it easy to share with employers, licensing bodies, or professional networks as evidence of your learning.
Note on scope. TerraLeap certificates confirm successful completion of the respective programme and recognise your professional development and continuing education. They do not constitute a professional licence or regulatory authorisation unless explicitly stated in the programme description.
TERRALEAP
Certificate ID
TL-2026-AB7K3X9P
Official
Seal
Certificate of Completion
Successfully Completed
Awarded in recognition of academic achievement
This is to certify that
XXXXX
has successfully completed the prescribed course of study, demonstrating commitment, diligence, and proficiency in
Pediatric Leukemias and Lymphomas
and is hereby awarded this certificate by TerraLeap, recognising the candidate's mastery of the syllabus and successful evaluation.